aflibercept-ayyh (Pavblu) vs CKD-701

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT04270747 · Phase 3 · completed

This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.

Reported efficacy

Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)

Result source: NCT04270747

CKD-701 · Lucenbies

Marketed by Chong Kun Dang Pharmaceutical

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Reliable signal

NCT04857177 · Phase 3 · completed

In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.

Reported efficacy

The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 3 months versus baseline. (Baseline to 3 months): Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). (met)

Result source: NCT04857177

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. aflibercept-ayyh (Pavblu): 4 of 4 rows · CKD-701: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricaflibercept-ayyh (Pavblu)CKD-701
Dropout rate
5.2%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—
Discontinued due to AEs
0.3%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—
Serious AEs
—ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
8.1%Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.1%Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—
Most frequent reported AEs
neovascular age-related macular degeneration 5.9%
conjunctival haemorrhage 1.5%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 1 more result
conjunctival haemorrhage 4.2%
neovascular age-related macular degeneration 2.1%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

aflibercept-ayyh (Pavblu)

BCVA Change Letters 6.4 vs 6.5 Aflibercept Letters @ 8wk
absolute change · Letters
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 8 more results
5 vs 5.4 Aflibercept Letters @ 4wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.5 vs 7.6 Aflibercept Letters @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.8 vs 7.5 Aflibercept Letters @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 7.1 Aflibercept Letters @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.1 vs 8.7 Aflibercept Letters @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.3 vs 8.1 Aflibercept Letters @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 8.7 Aflibercept Letters @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.6 vs 9.4 Aflibercept Letters @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintained Vision 95.6% (n=251) vs 97.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 10 Letters 29.4% (n=279) vs 32.7% (n=281) Aflibercept @ 8wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CNV Area Change Mm2 -4.962 vs -5.479 Aflibercept mm @ 8wk
absolute change · mm
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 3 more results
-4.089 vs -5.174 Aflibercept mm @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-4.323 vs -5.308 Aflibercept mm @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-6.276 vs -7.28 Aflibercept mm @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CST Change Microns -136.5 vs -143.1 Aflibercept m @ 4wk
absolute change · m
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
-145.9 vs -146.3 Aflibercept m @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-125.2 vs -127.3 Aflibercept m @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-130.8 vs -131.7 Aflibercept m @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-133.2 vs -134.1 Aflibercept m @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -135.6 Aflibercept m @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -141.1 Aflibercept m @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-157.1 vs -159.1 Aflibercept m @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

CKD-701

BCVA Loss Less Than 15 Letters 97.95% vs 98.62% ranibizumab/Lucentis @ 12.99wk
responder rate · % of participants
NCT04857177 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · CKD-701's landscape